- Home
- Current Affairs
- Current News
- FDA Approves Valneva's Single-Shot Vaccine for Chikungunya Virus
FDA Approves Valneva's Single-Shot Vaccine for Chikungunya Virus
Recently, the US Food and Drug Administration (FDA) has granted approval to Valneva's single-shot vaccine, Ixchiq, for individuals aged 18 and above, particularly those at an increased risk of exposure to the chikungunya virus, a mosquito-borne disease.
Key Points
- First US Approval: Valneva's Ixchiq becomes the inaugural preventive shot sanctioned in the United States for combatting the chikungunya virus, transmitted through mosquito bites.
- Chikungunya Symptoms: The virus typically causes symptoms such as fever, joint pain, headache, muscle pain, joint swelling, or rash in infected individuals.
- Late-Stage Trial Success: FDA's approval is founded on late-stage trials, revealing that the vaccine successfully generated antibody levels capable of neutralizing the chikungunya virus in 98.9% of participants within 28 days post-vaccination.
- Post-Marketing Study: Despite approval, the FDA has requested Valneva to conduct a post-marketing study to evaluate the potential risk of severe chikungunya-like adverse reactions following the administration of Ixchiq.
News Crux
News Crux
News Crux
- Appointment & Resignation
- Art/Culture/Heritage
- Awards In News
- Bill/Act/Amendment
- Defence
- Defence/Military Exercises
- Ecology & Environment
- Famous Books
- Important Days/Weeks
- Important Decade
- Miscellaneous
- Obituary
- Organisation In News
- Persons In News
- Places In News
- Plans & Policy
- Reports/Committee/Commission
- Scheme & Programme
- Science & Technology
- Species In News
- Summit, Seminars & Conferences
- Survey/Index
- Web Portal & Apps